Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Revenue projections:

Revenue projections for TECH
Revenue projections for TECH

Investors may react cautiously to news that TECH's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 4.547000
forwardPE 31.169752
debtToEquity 13.712000
earningsGrowth 0.000000
revenueGrowth 0.013000
grossMargins 0.662430
operatingMargins 0.234520
trailingEps 1.160000
forwardEps 2.316990

TECH's current ratio is 4.547, signaling that the company has sufficient cash reserves and current assets to cover its short-term debt obligations. This suggests financial stability, as TECH should not face any issues meeting its short-term liabilities with available resources.
TECH's low Debt-to-Equity ratio reflects that the company isn't heavily reliant on debt, reducing financial risk. This conservative approach suggests TECH maintains a stable financial foundation, with greater flexibility to manage future growth or challenges without over-leverage concerns.
TECH's positive gross and operating margins indicate strong financial performance. These margins show that the company is profitable and efficient in its operations, with effective cost control contributing to its overall financial success.
Bio-Techne Corporation's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that Bio-Techne Corporation's financial performance will improve in the current financial year.

Price projections:

Price projections for TECH
Price projections for TECH

Surpassing the higher limit of projections, TECH's stock price reflects significant gains. Yet, the restricted potential for further rises indicates that the stock may need to consolidate, possibly leading to increased volatility in the short term.

Insider Transactions:

Insider Transactions for TECH
Insider Transactions for TECH


3 TECH shares were sold in recent transactions, with market price at 54.52333323160807.No sell transactions occurred during the period under consideration.The higher number of buys versus sells near Bio-Techne Corporation's current price suggests optimism among investors. This buying trend could be interpreted as a sign that the market expects favorable outcomes for the stock in the near future.

Recommendation changes over time:

Recommendations trend for TECH
Recommendations trend for TECH


A recent buy bias from analysts toward TECH indicates strong confidence in the stock's future performance. This could encourage investors to park their money in TECH, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.